Project Grant R01AG088215

Award Date 9/15/24
Completion Date 5/31/29
Dollars Obligated $577K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
The National Institute on Aging awarded a $151,000 Project Grant (CFDA 93.866 Aging Research) to Ohio University to investigate the role of the keratin 18 protein in mediating skeletal muscle adaptation to exercise and age-related muscle loss (sarcopenia). The overarching goal is to determine if the upregulation of keratin 18 facilitates skeletal muscle resilience and adaptation to physical stress, especially in older individuals susceptible to sarcopenia and frailty. The project will examine...
This $381,507 Project Grant was awarded by the National Institute on Aging under the Aging Research federal grant program (CFDA 93.866) to the University of Iowa. The grant aims to study the role of the protein kinase ULK2 and its binding partner FIP200 in the selective degradation of protein aggregates in skeletal muscle, which could contribute to the development of age-related muscle atrophy and weakness (sarcopenia). The proposed research has two key objectives: 1) Establish ULK2's role in...
This Project Grant award of $387,006 from the National Institute on Aging (NIA) under CFDA Program 93.866 - Aging Research supports research to understand how indoles derived from commensal gut bacteria can promote mobility and counteract sarcopenia (age-related muscle wasting) in aging animals. The research aims to determine the mechanisms by which indoles regulate muscle protein homeostasis, mitochondrial function, and other cellular pathways to maintain muscle mass and function during...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research to examine the role of the MYC gene in regulating skeletal muscle function, metabolism, and age-related changes. The $141,890 award to the University of Arkansas will support the development of mouse models to investigate how MYC induction and exercise impact muscle at the cellular and molecular levels, including DNA methylation "clock" age. The research aims to provide...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, CFDA 93.846) provides $248,724 to the University of Alabama at Birmingham (UAB) to conduct research on the role of cellular senescence in skeletal muscle loss and dysfunction. The overarching objectives are to (1) obtain the necessary skills and training to develop a translational research program investigating mechanisms underlying skeletal muscle wasting, and (2) generate data to...
This $485,375 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support the development and evaluation of a 3D engineered muscle tissue model to study the metabolic response to muscle contraction in the context of aging. The University of Washington, a prominent research institution, will lead this 2-year project to: 1) examine the mitochondrial mechanisms underlying the decreased metabolic response to muscle contraction in aged human 3D engineered...
This $485,375 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research at the University of Washington to investigate genomic alterations in skeletal muscle associated with aging. The key objectives are to: Explore if alternative splicing of mRNA results in quantitative differential isoform changes associated with aging, potentially leading to increased expression of non-functional proteins relevant for healthy muscle function. The researchers...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $116,710 to Duke University to support Dr. David Lee's research on fibro/adipogenic progenitor (FAP) cell metabolism and its role in age-related muscle fibrosis and sarcopenia. The research aims to 1) determine the onset of FAP fibrogenesis during sarcopenia development, 2) assess whether increased FAP glycolysis drives fibrogenesis, and 3) investigate if Wnt signaling regulates FAP glycolysis and...
This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $287,218.16 in funding to the University of Maryland, Baltimore from August 1, 2021 through March 27, 2022. The award supports research aimed at better understanding the impact of aging on muscle excitability and action potential conduction velocity. Specifically, the recipient will use electrophysiology techniques and optical imaging to examine...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Washington provides $485,375 to investigate the mechanisms underlying reduced resilience and adaptability of aging skeletal muscle. The project aims to determine whether increased mitochondrial redox stress drives the impairment of redox stress response signaling and declining muscle function with age. The researchers will use skeletal muscle contraction as a model to examine the...

THE FUNCTION OF POST-TRANSLATIONAL MODIFICATIONS OF MYOSIN AND ITS CHAPERONE UNC-45 THAT OCCUR WITH ADULT AGING - PROJECT SUMMARY ONE OF THE UNFORTUNATE EFFECTS OF AGING IS THE LOSS OF MUSCLE MASS, STRENGTH, AND FUNCTION, TERMED "SARCOPENIA", WHEN IT IS NOT ASSOCIATED WITH AN UNDERLYING DISEASE. SARCOPENIA AFFECTS 40-50% OF INDIVIDUALS OVER 80 YEARS OF AGE, AND IS A MAJOR CONTRIBUTOR TO PHYSICAL DISABILITY, POOR QUALITY OF LIFE, AND DEATH AMONG THE ELDERLY. THE MOLECULAR MECHANISMS RESPONSIBLE FOR SARCOPENIA ARE NOT WELL-UNDERSTOOD. IN AGED MUSCLE, MYOSIN UNDERGOES CHEMICAL MODIFICATIONS THAT CORRELATE WITH ALTERATIONS IN ITS STRUCTURE AND DIMINISHED CONTRACTILE FUNCTION. GUIDED BY OUR PRELIMINARY STUDIES, WE HYPOTHESIZE THAT AGING LEADS TO ALTERED MYOSIN-CHAPERONE INTERACTIONS, AS A RESULT OF CHEMICAL MODIFICATIONS OF THESE PROTEINS THAT ACCUMULATE WITH AGE, ULTIMATELY CONTRIBUTING TO THE DIMINISHED MUSCLE MASS OF SARCOPENIA. THROUGH A UNIQUE COLLABORATION BETWEEN TWO EXPERT RESEARCH LABS, WE WILL TEST THIS HYPOTHESIS USING A NOVEL COMBINATION OF IN VITRO BIOCHEMICAL AND BIOPHYSICAL ASSAYS AND IN VIVO TECHNIQUES TO PROBE THE EFFECTS OF POST-TRANSLATIONAL MODIFICATIONS ON THE UNC-45/HSP90/MYOSIN SYSTEM DURING AGING. OUR PRELIMINARY DATA SHOW THAT DURING AGING OF ADULT C. ELEGANS THERE IS A TIME-DEPENDENT DECREASE IN THE STEADY STATE LEVELS OF THESE PROTEINS: FIRST HSP-90, THEN UNC-45 AND THEN MYOSIN. DURING AGING, WE ALSO OBSERVE A LOSS OF UNC-45 THAT IS CORRELATED WITH AN INCREASE IN PHOSPHORYLATION OF THE PROTEIN: WE HAVE IDENTIFIED SEVERAL SITES OF AGE-ASSOCIATED PTMS, INCLUDING A PHOSPHO-SERINE IN THE HSP-90 BINDING TPR REPEATS (S111) AND PHOSPHORYLATION OF TWO CONSERVED SERINES IN THE CHAPERONING DOMAIN OF UNC-45 (S659 AND S723). BASED ON OUR PRELIMINARY DATA, WE HYPOTHESIZE THAT AN IMPORTANT MECHANISM OF SARCOPENIA IS AGE-ASSOCIATED CHEMICAL MODIFICATIONS OF UNC-45 AND MYOSIN THAT REDUCE THE STABILITY AND/OR FUNCTION OF THESE CRUCIAL MUSCLE PROTEINS. IN THIS PROJECT, WE WILL USE A NOVEL COMBINATION OF BIOPHYSICAL AND IN VIVO TOOLS TO TEST THIS HYPOTHESIS AT MULTIPLE SCALES (PROTEIN TO MYOFIBRIL TO CELL TO ANIMAL). IN AIM 1, WE WILL TEST THE HYPOTHESIS THAT AGE-DEPENDENT PTMS OF UNC-45 REDUCE ITS STABILITY AND/OR CHAPERONE FUNCTION, THUS REDUCING THE ABILITY OF UNC- 45 TO REFOLD DAMAGED MYOSIN. IN AIM 2, WE WILL TEST THE HYPOTHESIS THAT AGE-DEPENDENT PTMS OF MYOSIN ALTER ITS STABILITY AND/OR MOTOR ACTIVITY. BY CREATING C. ELEGANS MUTANTS IN WHICH RESIDUES THAT NORMALLY UNDERGO POST- TRANSLATIONAL MODIFICATION CANNOT BE MODIFIED, WE WILL TEST THE HYPOTHESIS THAT SUCH CHANGES WILL RESULT IN DELAYED OR REDUCED SARCOPENIA. C. ELEGANS HAS PROVIDED VALUABLE INSIGHTS, TRANSLATABLE TO ALL ANIMALS, ON MYOFIBRIL ASSEMBLY AND MAINTENANCE, GENES RESPONSIBLE FOR LONGEVITY AND AGING, AND IS AN ESTABLISHED MODEL FOR STUDYING SARCOPENIA. OUR HYPOTHESES, IF CONFIRMED, WILL REPRESENT A NEW PARADIGM IN THE BIOLOGY OF SARCOPENIA, WITH POTENTIAL FOR NOVEL THERAPEUTIC APPROACHES, USING RATIONAL DRUG DESIGN TO TARGET DIFFERENT SPECIFIC ENZYMES (E.G., PROTEIN KINASES) TO PREVENT AGING-ASSOCIATED CHEMICAL MODIFICATIONS OF MYOSIN AND UNC-45, AND HENCE DELAYING THE ONSET OR REDUCING THE SEVERITY OF SARCOPENIA IN THE ELDERLY.

Posted 9/16/24, 12:00 AM